Literature DB >> 22844112

Proteinase 3, the autoantigen in granulomatosis with polyangiitis, associates with calreticulin on apoptotic neutrophils, impairs macrophage phagocytosis, and promotes inflammation.

Julie Gabillet1, Arnaud Millet, Magali Pederzoli-Ribeil, Pascale Tacnet-Delorme, Loïc Guillevin, Luc Mouthon, Philippe Frachet, Véronique Witko-Sarsat.   

Abstract

Proteinase 3 (PR3) is the target of anti-neutrophil cytoplasm Abs in granulomatosis with polyangiitis, a form of systemic vasculitis. Upon neutrophil apoptosis, PR3 is coexternalized with phosphatidylserine and impaired macrophage phagocytosis. Calreticulin (CRT), a protein involved in apoptotic cell recognition, was found to be a new PR3 partner coexpressed with PR3 on the neutrophil plasma membrane during apoptosis, but not after degranulation. The association between PR3 and CRT was demonstrated in neutrophils by confocal microscopy and coimmunoprecipitation. Evidence for a direct interaction between PR3 and the globular domain of CRT, but not with its P domain, was provided by surface plasmon resonance spectroscopy. Phagocytosis of apoptotic neutrophils from healthy donors was decreased after blocking lipoprotein receptor-related protein (LRP), a CRT receptor on macrophages. In contrast, neutrophils from patients with granulomatosis with polyangiitis expressing high membrane PR3 levels showed a lower rate of phagocytosis than those from healthy controls not affected by anti-LRP, suggesting that the LRP-CRT pathway was disturbed by PR3-CRT association. Moreover, phagocytosis of apoptotic PR3-expressing cells potentiated proinflammatory cytokine in vitro by human monocyte-derived macrophages and in vivo by resident murine peritoneal macrophages, and diverted the anti-inflammatory response triggered by the phagocytosis of apoptotic cells after LPS challenge in thioglycolate-elicited murine macrophages. Therefore, membrane PR3 expressed on apoptotic neutrophils might amplify inflammation and promote autoimmunity by affecting the anti-inflammatory "reprogramming" of macrophages.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22844112     DOI: 10.4049/jimmunol.1200600

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.

Authors:  Tian-Hui Yang; Lisa S St John; Haven R Garber; Celine Kerros; Kathryn E Ruisaard; Karen Clise-Dwyer; Gheath Alatrash; Qing Ma; Jeffrey J Molldrem
Journal:  J Immunol       Date:  2018-07-18       Impact factor: 5.422

Review 2.  Macrophages in vascular inflammation--From atherosclerosis to vasculitis.

Authors:  Tsuyoshi Shirai; Marc Hilhorst; David G Harrison; Jörg J Goronzy; Cornelia M Weyand
Journal:  Autoimmunity       Date:  2015-03-26       Impact factor: 2.815

3.  Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone.

Authors:  Mikhail G Kolonin; Anna Sergeeva; Daniela I Staquicini; Tracey L Smith; Christy A Tarleton; Jeffrey J Molldrem; Richard L Sidman; Serena Marchiò; Renata Pasqualini; Wadih Arap
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

4.  Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis.

Authors:  Arnaud Millet; Katherine R Martin; Francis Bonnefoy; Philippe Saas; Julie Mocek; Manal Alkan; Benjamin Terrier; Anja Kerstein; Nicola Tamassia; Senthil Kumaran Satyanarayanan; Amiram Ariel; Jean-Antoine Ribeil; Loïc Guillevin; Marco A Cassatella; Antje Mueller; Nathalie Thieblemont; Peter Lamprecht; Luc Mouthon; Sylvain Perruche; Véronique Witko-Sarsat
Journal:  J Clin Invest       Date:  2015-10-05       Impact factor: 14.808

Review 5.  Interleukin-9 and T helper type 9 cells in rheumatic diseases.

Authors:  F Ciccia; G Guggino; A Ferrante; P Cipriani; R Giacomelli; G Triolo
Journal:  Clin Exp Immunol       Date:  2016-08       Impact factor: 4.330

6.  Proteinase 3 Is a Phosphatidylserine-binding Protein That Affects the Production and Function of Microvesicles.

Authors:  Katherine R Martin; Chahrazade Kantari-Mimoun; Min Yin; Magali Pederzoli-Ribeil; Fanny Angelot-Delettre; Adam Ceroi; Cédric Grauffel; Marc Benhamou; Nathalie Reuter; Philippe Saas; Philippe Frachet; Chantal M Boulanger; Véronique Witko-Sarsat
Journal:  J Biol Chem       Date:  2016-03-09       Impact factor: 5.157

Review 7.  Clearance of apoptotic neutrophils and resolution of inflammation.

Authors:  Mallary C Greenlee-Wacker
Journal:  Immunol Rev       Date:  2016-09       Impact factor: 12.988

8.  Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.

Authors:  Haley L Peters; Satyendra C Tripathi; Celine Kerros; Hiroyuki Katayama; Haven R Garber; Lisa S St John; Lorenzo Federico; Ismail M Meraz; Jack A Roth; Boris Sepesi; Mourad Majidi; Kathryn Ruisaard; Karen Clise-Dwyer; Jason Roszik; Don L Gibbons; John V Heymach; Stephen G Swisher; Chantale Bernatchez; Gheath Alatrash; Samir Hanash; Jeffrey J Molldrem
Journal:  Cancer Immunol Res       Date:  2017-03-02       Impact factor: 11.151

Review 9.  Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).

Authors:  Brice Korkmaz; Adam Lesner; Stephanie Letast; Yassir K Mahdi; Marie-Lise Jourdan; Sandrine Dallet-Choisy; Sylvain Marchand-Adam; Christine Kellenberger; Marie-Claude Viaud-Massuard; Dieter E Jenne; Francis Gauthier
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

10.  New selective peptidyl di(chlorophenyl) phosphonate esters for visualizing and blocking neutrophil proteinase 3 in human diseases.

Authors:  Carla Guarino; Monika Legowska; Christophe Epinette; Christine Kellenberger; Sandrine Dallet-Choisy; Marcin Sieńczyk; Guillaume Gabant; Martine Cadene; Jérôme Zoidakis; Antonia Vlahou; Magdalena Wysocka; Sylvain Marchand-Adam; Dieter E Jenne; Adam Lesner; Francis Gauthier; Brice Korkmaz
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.